Literature DB >> 22728747

Fluorescence imaging of mitochondria in cultured skin fibroblasts: a useful method for the detection of oxidative phosphorylation defects.

Boel De Paepe1, Joél Smet, Arnaud Vanlander, Sara Seneca, Willy Lissens, Linda De Meirleir, Mado Vandewoestyne, Dieter Deforce, Richard J Rodenburg, Rudy Van Coster.   

Abstract

BACKGROUND: Protons are pumped from the mitochondrial matrix via oxidative phosphorylation (OXPHOS) into the intermembrane space, creating an electric membrane potential (ΔΨ) that is used for adenosine triphosphate (ATP) production. Defects in one or more of the OXPHOS complexes are associated with a variety of clinical symptoms, often making it difficult to pinpoint the causal mutation.
METHODS: In this article, a microscopic method for the quantitative evaluation of ΔΨ in cultured skin fibroblasts is described. The method using 5,5',6,6'-tetraethylbenzimidazolyl-carbocyanine iodide (JC-1) fluorescence staining was tested in a selection of OXPHOS-deficient cell lines.
RESULTS: A significant reduction of ΔΨ was found in the cell lines of patients with either an isolated defect in complex I, II, or IV or a combined defect (complex I + complex IV). ΔΨ was not reduced in the fibroblasts of two patients with severe complex V deficiency. Addition of the complex I inhibitor rotenone induced a significant reduction of ΔΨ and perinuclear relocalization of the mitochondria. In cells with a heteroplasmic mitochondrial DNA (mtDNA) defect, a more heterogeneous reduction of ΔΨ was detected.
CONCLUSION: Our data show that imaging of ΔΨ in cultured skin fibroblasts is a useful method for the evaluation of OXPHOS functioning in cultured cell lines.

Entities:  

Mesh:

Year:  2012        PMID: 22728747     DOI: 10.1038/pr.2012.84

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  6 in total

1.  Elevated Autophagy and Mitochondrial Dysfunction in the Smith-Lemli-Opitz Syndrome.

Authors:  Shaohua Chang; Gongyi Ren; Robert D Steiner; Louise Merkens; Jean-Baptiste Roullet; Zeljka Korade; Paul J DiMuzio; Thomas N Tulenko
Journal:  Mol Genet Metab Rep       Date:  2014

2.  Upregulation of Mitochondrial Content in Cytochrome c Oxidase Deficient Fibroblasts.

Authors:  Aviram Kogot-Levin; Ann Saada; Gil Leibowitz; Devorah Soiferman; Liza Douiev; Itamar Raz; Sarah Weksler-Zangen
Journal:  PLoS One       Date:  2016-10-25       Impact factor: 3.240

3.  POLG2 deficiency causes adult-onset syndromic sensory neuropathy, ataxia and parkinsonism.

Authors:  Lionel Van Maldergem; Arnaud Besse; Boel De Paepe; Emma L Blakely; Vivek Appadurai; Margaret M Humble; Juliette Piard; Kate Craig; Langping He; Pierre Hella; François-Guillaume Debray; Jean-Jacques Martin; Marion Gaussen; Patrice Laloux; Giovanni Stevanin; Rudy Van Coster; Robert W Taylor; William C Copeland; Eric Mormont; Penelope E Bonnen
Journal:  Ann Clin Transl Neurol       Date:  2016-11-16       Impact factor: 4.511

4.  Clinical Heterogeneity in MT-ATP6 Pathogenic Variants: Same Genotype-Different Onset.

Authors:  Sara Capiau; Joél Smet; Boel De Paepe; Yilmaz Yildiz; Mutluay Arslan; Olivier Stevens; Maxime Verschoore; Hedwig Stepman; Sara Seneca; Arnaud Vanlander
Journal:  Cells       Date:  2022-01-30       Impact factor: 6.600

Review 5.  Long range physical cell-to-cell signalling via mitochondria inside membrane nanotubes: a hypothesis.

Authors:  Felix Scholkmann
Journal:  Theor Biol Med Model       Date:  2016-06-06       Impact factor: 2.432

6.  The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival.

Authors:  Shanna Dewaele; Louis Delhaye; Boel De Paepe; Eric James de Bony; Jilke De Wilde; Katrien Vanderheyden; Jasper Anckaert; Nurten Yigit; Justine Nuytens; Eveline Vanden Eynde; Joél Smet; Maxime Verschoore; Fariba Nemati; Didier Decaudin; Manuel Rodrigues; Peihua Zhao; Aart Jochemsen; Eleonora Leucci; Jo Vandesompele; Jo Van Dorpe; Jean-Christophe Marine; Rudy Van Coster; Sven Eyckerman; Pieter Mestdagh
Journal:  Oncogene       Date:  2021-09-10       Impact factor: 9.867

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.